Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer

Immune checkpoint inhibitors in metastatic non-small-cell lung cancer are commonly used, either in patients with non-squamous disease, or in those with squamous disease but without ALK or EGFR mutations. 1 Hanna NH Schneider BJ Temin S et al. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2020; (published online Jan 28.)DOI:10.1200/JCO.19.03022 Crossref Scopus (84) Google Scholar In the IMpower130 trial, 2 West H McCleod M Hussein M et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20: 924-937 Summary Full Text Full Text PDF PubMed Scopus (389) Google Scholar patients who received atezolizumab, a monoclonal antibody against PD-L1 (1200 mg administered intravenously every 3 weeks), plus carboplatin (area under the curve 6 mg/mL per min every 3 weeks) and nab-paclitaxel (100 mg/m2 administered intravenously each week) for four or six 21-day cycles, had progression-free survival of 7·0 months, which was longer than that in patients who received chemotherapy alone (5·5 months; p<0·0001). Atezolizumab showed benefits regardless of PD-L1 expression. 2 West H McCleod M Hussein M et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20: 924-937 Summary Full Text Full Text PDF PubMed Scopus (389) Google Scholar Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trialAtezolizumab plus carboplatin and nab-paclitaxel could be a potential neoadjuvant regimen for resectable non-small-cell lung cancer, with a high proportion of patients achieving a major pathological response, and manageable treatment-related toxic effects, which did not compromise surgical resection. Full-Text PDF